Didier Mandelbrot, MD
Nephrology · Madison, WINPI 1295773596
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,900 of the $6,532 with a category attached, or 75.0%. CSL Behring accounts for 89.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $4,794 and has fallen 98.2% since, to $86 in 2025.
Across 11 payments — averaging $593.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$6K
- ZOLL Medical Corporation$467
- Takeda Pharmaceuticals U.S.A., Inc.$136
- Travere Therapeutics, Inc.$86
Across 44 payments — averaging $5816.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$254K
- Modernatx, Inc.$2K
What the payments were for
- Consulting fees$4677%
- Speaking & faculty fees$4,90075%
- Travel & lodging$88414%
- Food & beverage$2824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 7 | $5,844 |
| ZOLL Medical Corporation | 1 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $136 |
| Travere Therapeutics, Inc. | 1 | $86 |
How this compares
$6,532 in reported general payments places this provider in the 85th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolic AcidMycophenolate Sodium | 84 | $15,123 |
| Envarsus XrTacrolimus | 18 | $14,454 |
| Cinacalcet Hcl | 96 | $8,975 |
| Tacrolimus | 82 | $6,463 |
| Sirolimus | 19 | $4,365 |
| Prednisone | 685 | $3,863 |
| Valganciclovir Hcl | 14 | $3,601 |
| Nifedipine ErNifedipine | 173 | $3,545 |
| Carvedilol | 322 | $2,790 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 305 | $2,346 |
| Pantoprazole Sodium | 171 | $1,955 |
| Losartan Potassium | 189 | $1,728 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,606 |
| Calcitriol | 102 | $1,536 |
| Metoprolol Succinate | 66 | $1,445 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Madison
- Sandesh ParajuliMadison$12K
- Sayee Sundar AlagusundaramoorthyMadison$6K
- Andrey VavrenyukMadison$2K
- Gabino Maza RodasMadison$1K
- Nolan InterialMadison$815
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Rishi KoraGlendale$57K
- Manohar AhujaMilwaukee$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.